Cirrhosis
Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint
Clinical Pathway
Cirrhosis is a late-stage liver disease characterized by the irreversible replacement of healthy liver tissue with extensive scar tissue (fibrosis) and regenerative nodules, leading to impaired liver function and progressive liver failure. This scarring disrupts the liver's normal structure and blood flow, severely compromising its ability to perform vital functions. Treatment for cirrhosis primarily focuses on addressing the underlying cause to prevent further liver damage and managing complications. This involves abstaining from alcohol, antiviral therapy for hepatitis, immunosuppressants for autoimmune conditions, diuretics for fluid retention (ascites/edema), and lactulose or rifaximin for hepatic encephalopathy. Liver transplantation is the definitive treatment for end-stage decompensated cirrhosis. Early stages of cirrhosis are often asymptomatic. As the disease progresses, common symptoms include fatigue, weakness, unintentional weight loss, nausea, and anorexia. Signs of decompensated cirrhosis may manifest as jaundice, ascites, peripheral edema, hepatic encephalopathy (confusion, lethargy), spider angiomas, palmar erythema, and easy bruising or bleeding.
Clinical Reasoning
Chronic liver injury, regardless of etiology, triggers continuous inflammation and hepatocyte damage, leading to the activation of hepatic stellate cells. These activated cells produce excessive amounts of collagen and extracellular matrix components, which accumulate as dense fibrous tissue. This extensive fibrosis distorts the normal liver architecture, forming regenerative nodules and obstructing blood flow through the hepatic sinusoids, ultimately resulting in portal hypertension and progressive hepatocellular dysfunction. The prognosis for cirrhosis varies significantly depending on the underlying cause, the stage of the disease, and the development of complications. While compensated cirrhosis can be stable for years with proper management, decompensated cirrhosis carries a poor prognosis, with median survival significantly reduced without liver transplantation. Chronic viral hepatitis (Hepatitis B and C),Chronic alcohol abuse,Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH),Autoimmune hepatitis,Primary biliary cholangitis (PBC) and Primary sclerosing cholangitis (PSC),Hemochromatosis
Sample MCQ
A 65-year-old Saudi male with chronic Hepatitis C cirrhosis and multifocal hepatocellular carcinoma undergoes transarterial chemoembolization (TACE) targeting lesions in segments VII and VIII. The procedure is technically successful with no immediate complications. Forty-eight hours later, he develops severe epigastric pain radiating to his back, persistent nausea, vomiting of coffee-ground material, and melena. His hemoglobin has dropped from 12.5 to 10.1 g/dL. Which of the following is the most likely cause of this patient's symptoms?
- AGastric artery non-target embolization
- BSevere post-embolization syndrome
- CEsophageal variceal hemorrhage
- DAcute pancreatitis
Correct Answer: A
### TLDR The patient's acute upper GI bleeding symptoms, including coffee-ground emesis, melena, and significant hemoglobin drop, coupled with severe epigastric pain post-TACE, are highly indicative of gastric ischemia. This clinical picture is most consistent with inadvertent embolization of a gastric artery during the procedure. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :----- | :-------- | :-------------- | :-------------- | | **Gastric artery non-target embolization** | Inadvertent occlusion of gastric vessels during TACE, causing ischemia. | Severe epigastric pain, coffee-ground emesis, melena, Hgb drop. | Bleeding and pain directly result from gastric ischemia/ulceration. | | Severe post-embolization syndrome | Systemic inflammatory response to tumor necrosis and embolic agents. | Fever, right upper quadrant pain, nausea, vomiting; no GI bleed. | Lacks coffee-ground emesis, melena, and significant Hgb drop. | | Esophageal variceal hemorrhage | Rupture of esophageal varices due to portal hypertension in cirrhosis. | Hematemesis (often frank blood), melena; severe pain less common. | TACE-related timing and gastric-specific bleeding (coffee-ground). | | Acute pancreatitis | Inflammation of the pancreas, possibly from non-target pancreatic embolization. | Severe epigastric pain radiating to back, nausea, vomiting; no GI bleed. | Lacks coffee-ground emesis, melena, and significant Hgb drop. | ### Detailed Breakdown The patient's symptoms present a clear picture of acute upper gastrointestinal bleeding combined with severe visceral pain developing shortly after transarterial chemoembolization (TACE). **Gastric artery non-target embolization** is the most likely cause. TACE targets hepatic artery branches supplying hepatocellular carcinoma. The hepatic arterial supply often has anastomoses or shared origins with extrahepatic arteries, including the gastric (left gastric artery) and gastroduodenal arteries. Inadvertent embolization of these non-target vessels can lead to ischemia and necrosis of the stomach or duodenum. This ischemia manifests as severe epigastric pain (radiating to the back if gastric wall necrosis or perforation occurs), nausea, vomiting, and most critically, upper GI bleeding (coffee-ground emesis from gastric acid denaturing blood, melena from digested blood in the stool, and a significant hemoglobin drop). This perfectly aligns with the patient's presentation 48 hours post-procedure. **Severe post-embolization syndrome (PES)** is a common, self-limiting complication of TACE, characterized by fever, malaise, nausea, vomiting, and right upper quadrant pain due to tumor necrosis. While nausea and vomiting are present in this patient, the *severity* of pain radiating to the back, and especially the *coffee-ground emesis, melena, and significant hemoglobin drop*, are not typical features of PES. PES does not cause active GI bleeding. **Esophageal variceal hemorrhage** is a known complication in cirrhotic patients. It typically presents with frank hematemesis, melena, and signs of hypovolemia. While melena and hemoglobin drop are consistent, the "coffee-ground" emesis specifically points to gastric bleeding rather than esophageal bleeding. Additionally, severe epigastric pain radiating to the back is not a primary symptom of variceal hemorrhage itself, and the timing post-TACE makes a direct procedural complication more probable. **Acute pancreatitis** could cause severe epigastric pain radiating to the back, nausea, and vomiting, possibly if there was inadvertent embolization of pancreatic arteries. However, acute pancreatitis alone does not typically cause coffee-ground emesis, melena, and a significant hemoglobin drop. These bleeding symptoms strongly differentiate it from pancreatitis.
Related Clinical Topics
AIDS
AIDS (Acquired Immunodeficiency Syndrome) is the final, most severe stage of HIV infection, characterized by a profoundly compromised immune system that makes individuals highly susceptible to opportunistic infections and certain cancers. It is diagnosed when the CD4+ T-cell count drops below 200 cells/mm³ or when specific AIDS-defining opportunistic illnesses develop. The cornerstone of AIDS treatment is highly active antiretroviral therapy (HAART), a combination of drugs that suppress HIV replication, preserve immune function, and prevent further progression. HAART significantly reduces viral load, increases CD4+ T-cell counts, and improves overall health. Treatment also includes prophylactic antibiotics to prevent opportunistic infections and specific therapies for any active infections or cancers. Symptoms of AIDS are primarily due to the opportunistic infections and cancers that take advantage of the severely weakened immune system. Common manifestations include persistent fever, chronic diarrhea, significant unintentional weight loss, night sweats, fatigue, swollen lymph nodes, and recurrent severe infections like Pneumocystis pneumonia, Kaposi's sarcoma, and toxoplasmosis. Neurological complications such as AIDS dementia complex can also occur.
Bradycardia
Bradycardia is a medical condition characterized by a slower than normal heart rate, typically defined as fewer than 60 beats per minute (bpm) in adults. While sometimes physiological and benign, it can also indicate underlying cardiovascular or systemic issues that impair the heart's ability to effectively pump blood. Treatment for bradycardia depends on its underlying cause, severity, and the presence of symptoms. Asymptomatic bradycardia, especially in athletes, often requires no intervention. Symptomatic bradycardia may necessitate discontinuing or adjusting causative medications, treating underlying conditions, or in severe cases, implanting a permanent pacemaker to regulate heart rhythm. Acute, unstable bradycardia may require intravenous atropine or temporary pacing. Clinical manifestations range from asymptomatic presentation to severe symptoms depending on the degree of bradycardia and the patient's cardiovascular reserve. Common symptoms include fatigue, dizziness, lightheadedness, syncope (fainting), shortness of breath, and chest pain. In critical cases, it can lead to confusion, hypotension, and signs of organ hypoperfusion.
Chronic Hepatitis C Virus infection
Chronic Hepatitis C Virus (HCV) infection is a persistent inflammatory condition of the liver caused by the hepatitis C virus, defined by the presence of detectable HCV RNA for at least six months. This long-term infection can progressively lead to significant liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatment primarily involves direct-acting antiviral (DAA) medications, which are highly effective oral regimens targeting specific viral proteins to inhibit HCV replication. These therapies typically achieve a sustained virologic response (SVR) in over 95% of patients, effectively curing the infection. Treatment duration usually ranges from 8 to 12 weeks, depending on the specific regimen and patient factors. Chronic HCV infection is often asymptomatic for many years, leading to a silent progression of liver disease. When symptoms do appear, they are often non-specific, such as fatigue, malaise, nausea, and right upper quadrant discomfort. As the disease advances to cirrhosis, signs of liver decompensation may emerge, including jaundice, ascites, peripheral edema, spider angiomata, and hepatic encephalopathy.
SMLE Preparation Resources
Master the 2026 SMLE
Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.
Try the QBank & Scaled Mocks